Summer greetings from RhoVac
In 2015, RhoVac AB ("RhoVac") launched a focused three-year plan aimed at developing the company's drug candidate RV001, an immuno-oncology treatment, with the potential to prevent or limit the spread of cancer (metastasis). The current treatments (surgery, radiation and / or chemotherapy) of the mother tumor are relatively effective, but many of the patients experience serious side effects and the disease has a high risk of relapse. RhoVac’s focus is on preventing this relapse for which, the company is investing in the development of the drug candidate RV001. Today, three years later, we